Analytical validation of BD‐tau Advantage PLUS kit with clinical corroboration in a traumatic brain injury cohort

Abstract

Background: BD‐tau has emerged as a promising biomarker in predicting Alzheimer's disease‐specific neurodegeneration. However, to our knowledge, there is only one commercially available but not fully validated assay, the BD‐tau Advantage Plus kit (BD‐tau Adv Plus) from Quanterix, for measuring BD‐tau in plasma.

The paper